2026年9月16日•3 分钟阅读
MFDS Identifies GCP Gaps in Dayvigofilm Coating Tablet (Rembolexant) Approval Process
The Korean MFDS flagged protocol adherence, monitoring and record‑keeping issues in the clinical trial for Dayvigofilm coating tablet, though no serious violations were found.